Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.

Hojo T, Masuda N, Iwamoto T, Niikura N, Anan K, Aogi K, Ohnishi T, Yamauchi C, Yoshida M, Kinoshita T, Masuoka H, Sagara Y, Sakatani T, Kojima Y, Tsuda H, Kumamaru H, Miyata H, Nakamura S.

Breast Cancer. 2019 Jul 20. doi: 10.1007/s12282-019-00997-w. [Epub ahead of print]

PMID:
31327134
2.

Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience.

Kawamura K, Ichikado K, Ichiyasu H, Anan K, Yasuda Y, Suga M, Sakagami T.

BMC Pulm Med. 2019 Jun 25;19(1):113. doi: 10.1186/s12890-019-0880-0.

3.

A Scoring System with High-Resolution Computed Tomography to Predict Drug-Associated Acute Respiratory Distress Syndrome: Development and Internal Validation.

Anan K, Ichikado K, Ishihara T, Shintani A, Kawamura K, Suga M, Sakagami T.

Sci Rep. 2019 Jun 13;9(1):8601. doi: 10.1038/s41598-019-45063-9.

4.

Distinct Roles of the NAD+-Sirt1 and FAD-LSD1 Pathways in Metabolic Response and Tissue Development.

Nakao M, Anan K, Araki H, Hino S.

Trends Endocrinol Metab. 2019 Jul;30(7):409-412. doi: 10.1016/j.tem.2019.04.010. Epub 2019 May 28.

PMID:
31151734
5.

Role of Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer Patients: A Study from the Japanese Breast Cancer Registry.

Miyashita M, Niikura N, Kumamaru H, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Tsuda H, Nakamura S, Tokuda Y.

Ann Surg Oncol. 2019 Aug;26(8):2475-2485. doi: 10.1245/s10434-019-07453-1. Epub 2019 May 17.

PMID:
31102090
6.

The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.

Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T.

Lung Cancer. 2019 Apr;130:159-161. doi: 10.1016/j.lungcan.2019.02.011. Epub 2019 Feb 14.

PMID:
30885338
7.

Discovery of NR2B-selective antagonists via scaffold hopping and pharmacokinetic profile optimization.

Anan K, Masui M, Tazawa A, Tomida M, Haga Y, Kume M, Yamamoto S, Shinohara S, Tsuji H, Shimada S, Yagi S, Hasebe N, Kai H.

Bioorg Med Chem Lett. 2019 May 1;29(9):1143-1147. doi: 10.1016/j.bmcl.2019.02.017. Epub 2019 Feb 15.

PMID:
30833109
8.

Lysine-specific demethylase-2 is distinctively involved in brown and beige adipogenic differentiation.

Takase R, Hino S, Nagaoka K, Anan K, Kohrogi K, Araki H, Hino Y, Sakamoto A, Nicholson TB, Chen T, Nakao M.

FASEB J. 2019 Apr;33(4):5300-5311. doi: 10.1096/fj.201801422RR. Epub 2019 Jan 25.

PMID:
30681884
9.

[Follicle-Stimulating Hormone and Estradiol Levels in Japanese Women Treated with Toremifene and Anastrozole for Two Years - A Retrospective Analysis of Data from a Prospective Randomized Trial].

Anan K, Mitsuyama S, Yanagita Y, Kimura M, Doihara H, Komaki K, Kusama M, Ikeda T.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1725-1728. Japanese.

PMID:
30587728
10.

Dendriform Pulmonary Ossification.

Anan K, Hisanaga J, Kawamura K, Ichikado K.

Intern Med. 2019 Apr 1;58(7):1043-1044. doi: 10.2169/internalmedicine.1764-18. Epub 2018 Dec 18. No abstract available.

11.

The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.

Sakata Y, Kawamura K, Shingu N, Hiroshige S, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Nakano A, Ichikado K.

Asia Pac J Clin Oncol. 2018 Dec 2. doi: 10.1111/ajco.13103. [Epub ahead of print]

PMID:
30506897
12.
13.

Synthesis of a 6-CF3-Substituted 2-Amino-dihydro-1,3-thiazine β-Secretase Inhibitor by N, N-Diethylaminosulfur Trifluoride-Mediated Chemoselective Cyclization.

Oguma T, Anan K, Suzuki S, Hisakawa S, Takada A, Ogawa M, Kusakabe KI.

J Org Chem. 2019 Apr 19;84(8):4893-4897. doi: 10.1021/acs.joc.8b02179. Epub 2018 Oct 29.

PMID:
30371078
14.

The decision to perform or omit sentinel lymph node biopsy during mastectomy for ductal carcinoma in situ should be tailored in accordance with preoperative findings.

Watanabe Y, Anan K.

Breast Cancer. 2019 Mar;26(2):261-262. doi: 10.1007/s12282-018-0917-x. Epub 2018 Oct 16. No abstract available.

PMID:
30328007
15.

A case of primary extraskeletal osteosarcoma of the breast.

Kurata K, Anan K, Ishikawa N, Koga K, Saimura M, Nishihara K, Iwashita T, Mitsuyama S, Tamiya S, Watanabe H, Koga Y, Yamamoto H, Oda Y, Nakano T.

Surg Case Rep. 2018 Sep 19;4(1):121. doi: 10.1186/s40792-018-0530-4.

16.

[A Case of Metaplastic Squamous Cell Carcinoma of the Breast Diagnosed after Neoadjuvant Chemotherapy].

Ishikawa N, Saimura M, Koga K, Anan K, Mitsuyama S, Tamiya S.

Gan To Kagaku Ryoho. 2018 Jul;45(7):1101-1103. Japanese.

PMID:
30042281
17.

"Pulmonary Actinomycosis attributable to Actinomyces meyeri presenting as cardiac tamponade: a case report".

Nishizawa S, Anan K, Tobino K, Okahisa M, Goto Y, Murakami K, Sueyasu T, Munechika M, Yoshimine K, Yoshino M.

Multidiscip Respir Med. 2018 Jun 14;13:19. doi: 10.1186/s40248-018-0132-9. eCollection 2018.

18.

Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy.

Watanabe Y, Anan K, Saimura M, Koga K, Fujino M, Mine M, Tamiya S, Nishihara K, Nakano T, Mitsuyama S.

Breast Cancer. 2018 Nov;25(6):663-670. doi: 10.1007/s12282-018-0871-7. Epub 2018 May 21.

PMID:
29786772
19.

LSD1 mediates metabolic reprogramming by glucocorticoids during myogenic differentiation.

Anan K, Hino S, Shimizu N, Sakamoto A, Nagaoka K, Takase R, Kohrogi K, Araki H, Hino Y, Usuki S, Oki S, Tanaka H, Nakamura K, Endo F, Nakao M.

Nucleic Acids Res. 2018 Jun 20;46(11):5441-5454. doi: 10.1093/nar/gky234.

20.

Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center.

Kawamura K, Ichikado K, Takaki M, Eguchi Y, Anan K, Suga M.

Int J Antimicrob Agents. 2018 Jun;51(6):918-924. doi: 10.1016/j.ijantimicag.2018.02.009. Epub 2018 Feb 28.

PMID:
29501821
21.

Diagnosis, characteristics, and treatment of breast carcinomas within benign fibroepithelial tumors.

Saimura M, Koga K, Anan K, Mitsuyama S, Tamiya S.

Breast Cancer. 2018 Jul;25(4):470-478. doi: 10.1007/s12282-018-0847-7. Epub 2018 Feb 19.

PMID:
29460095
22.

Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.

Shien T, Doihara H, Sato N, Anan K, Komaki K, Miyauchi K, Yanagita Y, Fujisawa T, Mitsuyama S, Kanbayashi C, Kusama M, Kimura M, Jinno H, Sano M, Ikeda T.

Cancer Chemother Pharmacol. 2018 Feb;81(2):269-275. doi: 10.1007/s00280-017-3491-6. Epub 2017 Dec 1.

23.
24.

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S.

Curr Med Res Opin. 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426. Epub 2017 Nov 21.

PMID:
29095648
25.

Discovery of orally bioavailable cyclohexanol-based NR2B-selective NMDA receptor antagonists with analgesic activity utilizing a scaffold hopping approach.

Anan K, Masui M, Hara S, Ohara M, Kume M, Yamamoto S, Shinohara S, Tsuji H, Shimada S, Yagi S, Hasebe N, Kai H.

Bioorg Med Chem Lett. 2017 Sep 1;27(17):4194-4198. doi: 10.1016/j.bmcl.2017.06.076. Epub 2017 Jul 5.

PMID:
28754363
26.

Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study.

Kawamura K, Ichikado K, Yasuda Y, Anan K, Suga M.

BMC Pulm Med. 2017 Jun 19;17(1):94. doi: 10.1186/s12890-017-0437-z.

27.

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M.

Breast Cancer Res Treat. 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23.

PMID:
28337663
28.

Multinodular lung infiltrate in a patient with lymphoma: metastasis, tuberculosis or other?

Anan K, Kawamura K, Mitsui N, Ichikado K.

Oxf Med Case Reports. 2017 Mar 3;2017(3):omx006. doi: 10.1093/omcr/omx006. eCollection 2017 Mar.

29.

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.

Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Kinoshita T, Nakamura S, Tokuda Y.

Breast Cancer Res Treat. 2016 Nov;160(1):163-172. Epub 2016 Sep 19.

30.

Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis.

Kawamura K, Ichikado K, Takaki M, Sakata Y, Yasuda Y, Shingu N, Tanaka A, Hisanaga J, Eguchi Y, Anan K, Nitawaki T, Suga M.

Springerplus. 2016 Jul 28;5(1):1193. doi: 10.1186/s40064-016-2866-1. eCollection 2016.

31.

Distinct breast cancer characteristics between screen- and self-detected breast cancers recorded in the Japanese Breast Cancer Registry.

Iwamoto T, Kumamaru H, Miyata H, Tomotaki A, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Matsuoka J, Doihara H, Kinoshita T, Nakamura S, Tokuda Y.

Breast Cancer Res Treat. 2016 Apr;156(3):485-494. doi: 10.1007/s10549-016-3770-7. Epub 2016 Apr 5.

32.

Body mass index and survival after diagnosis of invasive breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.

Kawai M, Tomotaki A, Miyata H, Iwamoto T, Niikura N, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y.

Cancer Med. 2016 Jun;5(6):1328-40. doi: 10.1002/cam4.678. Epub 2016 Feb 29.

33.

Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.

Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, Hayashi N, Aogi K, Ishida T, Masuoka H, Iijima K, Masuda S, Tsugawa K, Kinoshita T, Nakamura S, Tokuda Y.

Ann Oncol. 2016 Mar;27(3):480-7. doi: 10.1093/annonc/mdv611. Epub 2015 Dec 23.

PMID:
26704052
34.

Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006.

Iwamoto T, Fukui N, Kinoshita T, Anan K, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y.

Breast Cancer. 2016 Jan;23(1):62-72. doi: 10.1007/s12282-015-0646-3. Epub 2015 Oct 13. No abstract available.

35.

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005.

Anan K, Fukui N, Kinoshita T, Iwamoto T, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y.

Breast Cancer. 2016 Jan;23(1):50-61. doi: 10.1007/s12282-015-0645-4. Epub 2015 Oct 13. No abstract available.

36.

Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004.

Kinoshita T, Fukui N, Anan K, Iwamoto T, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y.

Breast Cancer. 2016 Jan;23(1):39-49. doi: 10.1007/s12282-015-0644-5. Epub 2015 Oct 7. No abstract available.

37.

Lysine Demethylase LSD1 Coordinates Glycolytic and Mitochondrial Metabolism in Hepatocellular Carcinoma Cells.

Sakamoto A, Hino S, Nagaoka K, Anan K, Takase R, Matsumori H, Ojima H, Kanai Y, Arita K, Nakao M.

Cancer Res. 2015 Apr 1;75(7):1445-56. doi: 10.1158/0008-5472.CAN-14-1560. Epub 2015 Feb 3.

38.

Lysine-specific demethylase 2 suppresses lipid influx and metabolism in hepatic cells.

Nagaoka K, Hino S, Sakamoto A, Anan K, Takase R, Umehara T, Yokoyama S, Sasaki Y, Nakao M.

Mol Cell Biol. 2015 Apr;35(7):1068-80. doi: 10.1128/MCB.01404-14. Epub 2015 Jan 26.

39.

[Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].

Anan K, Tanaka M, Yoshinaga Y, Maeda S, Yamaguchi Y, Hayashi M, Tanaka M, Kamata Y, Mashino K, Yamamoto Y, Nishimura J, Matsuo S, Toyoshima S, Tamura K, Mitsuyama S; Kuyshu Brest Cancer Study Group.

Gan To Kagaku Ryoho. 2015 Jan;42(1):45-50. Japanese.

PMID:
25596678
40.

Effect of time pressure on attentional shift and anticipatory postural control during unilateral shoulder abduction reactions in an oddball-like paradigm.

Anan K, Fujiwara K, Yaguchi C, Kiyota N.

J Physiol Anthropol. 2014 Jun 27;33:17. doi: 10.1186/1880-6805-33-17.

41.

Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study.

Toi M, Hirota S, Tomotaki A, Sato N, Hozumi Y, Anan K, Nagashima T, Tokuda Y, Masuda N, Ohsumi S, Ohno S, Takahashi M, Hayashi H, Yamamoto S, Ohashi Y.

Curr Nutr Food Sci. 2013 Aug;9(3):194-200.

42.

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.

Nishimura R, Anan K, Yamamoto Y, Higaki K, Tanaka M, Shibuta K, Sagara Y, Ohno S, Tsuyuki S, Mase T, Teramukai S.

Oncol Rep. 2013 May;29(5):1707-13. doi: 10.3892/or.2013.2312. Epub 2013 Feb 27.

43.

Endoscopy-assisted breast-conserving surgery for early breast cancer.

Saimura M, Mitsuyama S, Anan K, Koga K, Watanabe M, Ono M, Toyoshima S.

Asian J Endosc Surg. 2013 Aug;6(3):203-8. doi: 10.1111/ases.12018. Epub 2013 Feb 1.

PMID:
23368666
44.

Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001).

Nishimura R, Arima N, Toyoshima S, Ohi Y, Anan K, Sagara Y, Mitsuyama S, Tamura K.

Mol Clin Oncol. 2013 Jan;1(1):47-52. Epub 2012 Aug 9.

45.

Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.

Nishimura R, Rai Y, Matsuo F, Anan K, Hara S, Imamura S, Itoyanagi N, Kato M, Okido M, Kudaka M, Ishikawa E, Kamada Y, Watanabe R, Shirouzu M, Mitsuyama S, Takamatsu Y, Tamura K.

Anticancer Res. 2012 Aug;32(8):3259-65.

PMID:
22843900
46.

[A multicenter study of epirubicin-docetaxel(ET)as primary chemotherapy for patients with inflammatory breast cancer(IBC)].

Saimura M, Anan K, Mitsuyama S, Toyoshima S, Ikejiri K, Ohchi T, Rai Y, Oikawa T, Kudaka M, Nishimura R, Kuroki S, Namba K, Nakafusa Y, Tamura K.

Gan To Kagaku Ryoho. 2012 Jul;39(7):1075-9. Japanese.

PMID:
22790042
47.

Ductal carcinoma in situ arising in tubular adenoma of the breast.

Saimura M, Anan K, Mitsuyama S, Ono M, Toyoshima S.

Breast Cancer. 2015 Jul;22(4):428-31. doi: 10.1007/s12282-012-0375-9. Epub 2012 Jun 15.

48.

[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study].

Anan K, Tanaka M, Mitsuyama S, Imamura S, Ohno S, Hara S, Oikawa T, Fujii T, Nishimura R, Ishikawa E, Yano H, Taniguchi H, Ohkido M, Ohchi T, Chijiiwa K, Arime I, Shimada K, Inoue H, Tamura K; Kyushu Breast Cancer Study Group (KBC-SG).

Gan To Kagaku Ryoho. 2012 May;39(5):747-52. Japanese.

PMID:
22584325
49.

FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure.

Hino S, Sakamoto A, Nagaoka K, Anan K, Wang Y, Mimasu S, Umehara T, Yokoyama S, Kosai K, Nakao M.

Nat Commun. 2012 Mar 27;3:758. doi: 10.1038/ncomms1755.

50.

Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.

Anan K, Mitsuyama S, Yanagita Y, Kimura M, Doihara H, Komaki K, Kusama M, Ikeda T.

Breast Cancer Res Treat. 2011 Aug;128(3):775-81. doi: 10.1007/s10549-011-1608-x. Epub 2011 Jun 3.

PMID:
21638048

Supplemental Content

Support Center